T. Rowe Price Associates
MIST icon

T. Rowe Price Associates’s Milestone Pharmaceuticals MIST Stock Holding History

T. Rowe Price Associates’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-267,997
Closed -$1.55M – 2943
2021
Q1 		$1.55M Sell
267,997
-106,960
-29% -$783K ﹤0.01% 1832
2020
Q4 		$2.51M Sell
374,957
-201,746
-35% -$1.35M ﹤0.01% 1567
2020
Q3 		$4.22M Sell
576,703
-63,483
-10% -$455K ﹤0.01% 1423
2020
Q2 		$2.42M Buy
640,186
+55,571
+10% +$179K ﹤0.01% 1498
2020
Q1 		$1.08M Sell
584,615
-701,892
-55% -$12.2M ﹤0.01% 1672
2019
Q4 		$20.6M Sell
1,286,507
-14,139
-1% -$250K ﹤0.01% 1175
2019
Q3 		$22.5M Buy
1,300,646
+700
+0.1% +$13.8K ﹤0.01% 1113
2019
Q2 		$35.3M Buy
+1,299,946
New +$26.8M 0.01% 997

Other funds holding MIST

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

T. Rowe Price Associates's MIST Position: Q2 2021 in Review

T. Rowe Price Associates sold out of Milestone Pharmaceuticals (MIST) in Q2 2021, closing a stake of 267,997 shares — an estimated $1.55M sold.

T. Rowe Price Associates first reported a position in MIST in Q2 2019 and held it in 8 quarters. The position peaked at $35.3M in Q2 2019. 28 funds tracked by Wall St. Rank hold MIST as of Q2 2021.

  • T. Rowe Price Associates reported no remaining Milestone Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 267,997 Milestone Pharmaceuticals shares in Q2 2021, an estimated $1.55M.
  • T. Rowe Price Associates first reported a position in Milestone Pharmaceuticals in Q2 2019 and held it in 8 quarters.
  • T. Rowe Price Associates's Milestone Pharmaceuticals position peaked at $35.3M in Q2 2019.
  • 28 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q2 2021.

Based on T. Rowe Price Associates's 13F filing for Q2 2021, filed 16 Aug 2021.